Turkish Journal of Medical Sciences
Volume 47

Number 3

Article 13

1-1-2017

Performing ICSI with commercial microinjection pipettes
enhanced pregnancy rates
MOHAMMAD ALI KHALILI
IMAN HALVAEI
SHAHIN GHAZALI
MOHAMMAD HOSSEIN RAZI

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
KHALILI, MOHAMMAD ALI; HALVAEI, IMAN; GHAZALI, SHAHIN; and RAZI, MOHAMMAD HOSSEIN (2017)
"Performing ICSI with commercial microinjection pipettes enhanced pregnancy rates," Turkish Journal of
Medical Sciences: Vol. 47: No. 3, Article 13. https://doi.org/10.3906/sag-1512-69
Available at: https://journals.tubitak.gov.tr/medical/vol47/iss3/13

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2017) 47: 801-805
© TÜBİTAK
doi:10.3906/sag-1512-69

http://journals.tubitak.gov.tr/medical/

Research Article

Performing ICSI with commercial microinjection pipettes enhanced pregnancy rates
1

2

3

1,

Mohammad Ali KHALILI , Iman HALVAEI , Shahin GHAZALI , Mohammad Hossein RAZI *
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2
Department of Anatomical Sciences, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3
Sanandaj Branch, Islamic Azad University, Sanandaj, Iran
1

Received: 11.12.2015

Accepted/Published Online: 14.11.2016

Final Version: 12.06.2017

Background/aim: Many technical factors can affect intracytoplasmic sperm injection (ICSI) outcomes. The role of the injection
micropipette could be of vital importance in ICSI programs. The main goal was to compare ICSI pregnancy outcomes between
commercial and home-made injection micropipettes in a large population with male factor infertility.
Materials and methods: Five-hundred and eleven ICSI cycles with severe male factor were included in this retrospective study. ICSI
cycles were divided into two groups: A (home-made micropipettes, n = 267) and B (commercial micropipettes, n = 244). Rates of
fertilization, embryo formation, and chemical and clinical pregnancies were compared between the groups. The independent samples
t-test, chi-square test, and Fisher’s exact test were used, whenever appropriate, for statistical analysis.
Results: A total of 3621 MII oocytes were retrieved, of which 2003 were fertilized. The rate of normal fertilization was significantly
higher in group A (57.9%) compared to group B (52.5%). However, the rate of embryo formation showed an increase in group B
compared to group A (90.4% and 85.9%, respectively, P = 0.002). In addition, the clinical pregnancy outcomes improved in group B.
Conclusion: Our findings indicate that clinical pregnancy improves when commercial injection micropipettes are used in ICSI programs.
Key words: Commercial micropipette, home-made micropipette, male infertility, ICSI outcome

1. Introduction
Micromanipulation technology has become one of
the principle techniques in new fields of biomedical
sciences, including chimera production, nuclear transfer,
and cytoplasmic transfer in order to improve embryo
development. It also establishes transgenic animals through
injection of pronuclear DNA content, preimplantation
embryo genetic diagnosis using blastomere biopsy,
embryo splitting, and intracytoplasmic sperm injection
(ICSI) (1–4).
Introduction of ICSI was the most effective treatment
program in order to give the opportunity of having
babies for couples with male factor infertility; also it
can improve the fertilization rate and embryo quality in
patients with nonmale factor infertility (5,6). The valuable
laboratory outcomes of ICSI could be oocyte survival rate,
fertilization rate, and formation of good quality embryos.
Many technical factors may affect ICSI outcomes, such as
sperm immobilization prior to ICSI (7), operator skill (8),
polyvinylpyrrolidone (PVP) (9), orientation of the first
polar body (10), injection micropipette (11), aspiration
of ooplasm (12), sperm direction inside the micropipette
* Correspondence: raziir@yahoo.com

(13), excessive manipulation inside the oocyte (14), effect
of sperm entry (15), and the ICSI technique itself (16).
Undoubtedly, one of the most important goals in assisted
reproductive technologies (ARTs) is to improve the
formation of high quality embryos to increase the chance
of pregnancy among infertile couples. Despite impressive
improvement in the ICSI technique, the rate of fertilization
in the majority of ART programs (60%–70%) is far from
ideal and needs further improvement (17).
One way to improve fertilization rate in ICSI programs
is to avoid or minimize oocyte degeneration. ICSI is an
invasive technique in which one spermatozoon is directly
injected into the ooplasm of a mature oocyte using a fine
glass micropipette. A well-designed micropipette with
passing mouse embryo assay (MEA) threshold may cause
less damage to the oocyte and reduces degeneration, while
increasing the normal fertilization rate. The vital role of the
injection micropipette in ICSI outcome has been shown
in only one previous study (11). The present retrospective
analysis was designed to compare ICSI outcomes using
commercial versus home-made injection micropipettes in
a large population with severe male factor infertility.
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2. Materials and methods
2.1. Patients
A total of 511 ICSI cycles of severe male factor infertility
that were referred to the research and clinical center for
infertility in Yazd, Iran, were reviewed retrospectively
from November 2014 to November 2015. Cycles were
divided into two groups: A (home-made micropipettes, n
= 267) and B (commercial micropipettes, n = 244). Semen
samples were collected by masturbation. Nonejaculated
spermatozoa, egg donation, and in-vitro matured oocytes
were excluded from the study. This study was approved
by our institute’s ethics committee (Ref. No: 2458) and all
patients signed informed consents.
2.2. Ovarian hyperstimulation and sperm preparation
GnRH agonist (Sanofi-Aventis, Germany) downregulation
followed by rFSH (Merck-Serono, Switzerland) was used
for ovarian hyperstimulation. Then 10,000 IU of human
chorionic gonadotrophin (hCG, i.m.; IBSA, Switzerland)
was administered. The ovarian response was checked by
transvaginal ultrasonography and evaluating the level of
serum estradiol. Approximately, 36 h after hCG injection,
oocyte pickup was done under transvaginal ultrasound
guidance (18).
Semen analysis was done according to WHO guidelines
(19). All sperm preparations were performed using the
swim-up or density gradient centrifugation techniques
(20,21). The ICSI procedure was conducted using fresh
samples as described previously (22).
2.3. Micropipette preparation
After washing the bororsilicate capillaries (Drummond,
USA) with milli-Q water, they were pulled by horizontal
pipette puller (Sutter Instrument Co., USA). For making
the injection micropipette, the pipette was ground. The
grinder (EG4, Narishige, Japan) whetstone was rotated at
1500 rpm with continues dripping of milli-Q water during
the rotation. The angle of the pipette with the whetstone
was 45°. The micropipette was washed with hydrofluoric
acid 0.1% for getting rid of any remaining glass debris
in the micropipette. Then the clean micropipette was
washed in deionized water several times. For bending
the micropipette, with aid of a heating microforge (MF9,
Narishige, Japan), an angle of 35°–40° was formed with an
inner diameter of 4–5 µm. For preparation of the holding
pipette, it was heated by microforge after pulling. The
bending was the same as above. The inner and opening
diameters were 12–15 and 3–5 µm, respectively. After
preparation, the micropipettes were sterilized by dry heat at
120 °C for 6 h. The inner diameter of commercial injection
micropipette (Vitrolife, Sweden) was 4–5.5 µm with a
bending angle of 30°. Each commercial micropipettte
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had already been tested with MEA by the manufacturing
company.
2.4. Fertilization and embryo evaluation
After ICSI, the injected oocytes were washed in equilibrated
culture medium and placed in 50-µL drops of G1 medium
(Vitrolife, Sweden) covered with mineral oil (Ovoil,
Vitrolife, Sweden). The injected oocytes were checked 16–
18 h post-ICSI for normal fertilization (presence of two
pronuclei and two polar bodies). Embryo transfer (ET)
was done on day 2. Only high-grade embryos with no or
minimal cytoplasmic fragmentation were transferred.
2.5. Pregnancy outcomes
Chemical pregnancy was determined by a positive βhCG
level 14 days after ET. Clinical pregnancy was determined
by visualization of the gestational sac in ultrasonographic
images or by detection of fetal heartbeat. Once chemical
pregnancy was confirmed at the end of the second week
of gestation, the patients were followed for 4 weeks for
clinical pregnancy assessment.
2.6. Statistical analysis
The data are presented as mean ± SD. The Mann–Whitney
test was used for comparison of quantitative data between
the two groups. The chi-square and Fisher’s exact tests
were used whenever appropriate using SPSS 16 (Chicago,
MI, USA). The odds ratio with 95% confidence interval is
also presented. The odds ratios were referred to the rates
of fertilized oocytes, embryo formation, and chemical and
clinical pregnancy. All tests were hypothesized two tailed
and P-values less than 0.05 were considered statistically
significant.
3. Results
A total of 3621 MII oocytes were retrieved, of which 2003
were fertilized normally. Patient characteristics are shown
in the Table. In groups A and B, 15 and 17 cycles were
missed to follow their pregnancy outcomes, respectively.
The rate of normal fertilization was significantly higher
in group A compared to group B (57.9% and 52.5%,
respectively, P = 0.001). However, the rate of embryo
formation showed a significant increase in group B
compared to group A (90.4% and 85.9%, respectively, P =
0.002). Higher pregnancy rates were reported in ICSI cases
with commercial injection micropipettes (Table).
4. Discussion
The design and quality of the microinjection needle is one
of the most important factors in successful ICSI programs
(23). There are several studies in this field and some
of the characteristics of micropipettes, e.g., sharpness
(24,25), inner diameter (11), and multiple pipette use
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Table. Intracytoplasmic sperm injection outcomes in groups A (home-made micropipette) and B (commercial micropipette).
Variables

Group B

267

244

31 (18–46)

30 (18–48)

0.009

6 (1–37)

6 (1–20)

0.08

Transferred embryos a

2 (1–4)

2 (1–4)

0.6

2 PN %

(1061/1830) 57.9

(942/1791) 52.5

0.001

1.2 (1–1.4)

Embryo formation %

(912/1061) 85.9

(852/942) 90.4

0.002

0.6(0.4–0.8)

Chemical pregnancy %

(72/252) 28.5

(71/227) 31.2

0.5

0.8 (0.5–1.3)

Clinical pregnancy %

(52/252) 20.6

(50/227) 22.0

0.7

0.9 (0.5–1.4)

No. of cycles
Female age

a

Metaphase ІІ oocytes

a

P

Odds ratio
(95% CI)

Group A

a: data are shown as median (min–max)
PN: pronuclear
CI: confidence interval

(26), have been evaluated previously. In this retrospective
investigation, we assessed ICSI outcomes between two
different injection micropipettes, namely commercial and
home-made. We tried to omit some confounding factors,
such as source of sperm, as only ejaculated spermatozoa
were included in the study. One of the important factors
that may affect the rate of fertilization in ICSI is the
operator’s skill (8). In our study, ICSI was performed
by two expert embryologists with at least 7 years of
experience. Moreover, ICSI by one embryologist would be
ideal in order to minimize interindividual variability in the
ICSI technique.
Another common factor in the two groups was the
holding micropipette, which was also home-made in all
cases. The inner diameter of the injection pipette can affect
the fertilization rate, and a smaller inner diameter can
improve the fertilization rate and embryo development
(11). It seems that there were no considerable differences
between the inner diameters of the commercial and
home-made micropipettes in the present study. The
inner diameters of both commercial and home-made
micropipettes were similar (4.5–5 µm vs. 4–5 µm).
However, both the sizes and diameters of the commercial
pipettes were more consistent compared to the homemade micropipettes. This factor may be one of the
advantages of using commercial micropipettes. The other
characteristics of the commercial micropipettes are the
sterilization method. One of the major differences with
the home-made ones is that the commercial micropipettes
importantly passed quality control tests (e.g., MEA,
endotoxin). The commercial pipettes seem to be more
cost-effective, as in-house preparations of micropipettes

require expensive instruments and expert operators.
One of the variable factors between the two groups is
the internal angle; the internal angles in groups A and B
were 35°–40º and 30°, respectively. This factor also may
not affect the ICSI outcomes, because the angle for the
injection micropipette can vary from 30° (27) to 45° (28).
As shown in Figure 1a, the distal arm in the home-made
micropipettes is 5–6 times higher when compared to the
commercial ones. In addition, the spike’s length in the
home-made micropipettes is about twice the length of
the spike in the commercial ones (Figure 1b). It may have
some detrimental impacts on the oocyte during ICSI, such
as rupture of the opposite side of the oolemma. Another
difference is related to the angle between the distal and
proximal arms, which is slightly higher in the home-made
micropipettes.
To the best of our knowledge, this is the first study
to compare the outcomes between home-made and
commercial microinjection needles for ICSI, which is
widely practiced in the treatment of male infertility.
However, there are some shortcomings of the study, such
as: 1) lack of comparison of oocyte degeneration rates
following ICSI between the two groups, and 2) lack of
comparison of nonfertilized and abnormally fertilized
(3PN) rates between the groups. We suggest conducting a
study comparing the role of commercial with home-made
micropipettes for immobilization of spermatozoa using
nonejaculated samples in the ICSI setting. In conclusion,
in comparison with home-made injection micropipettes,
it seems that the commercial injection micropipettes can
improve the rate of clinical pregnancy in ICSI programs in
large populations of male factor infertility.
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Figure 1a. Comparison of distal and proximal arm and internal
angle between home-made (A) and commercial micropipettes
(B).

Figure 1b. Comparison of spike length between home-made (A)
and commercial micropipettes (B).
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